HAWTHORNE, NY--(BUSINESS WIRE)--Oct. 1, 2004--Taro Pharmaceutical Industries Ltd. ("Taro," Nasdaq: TARO) today announced the retirement of Aaron Levitt, President of the Company. Mr. Levitt has built a distinguished career as a pharmaceutical and cosmetics executive over more than 30 years, during
HAWTHORNE, N.Y., Aug. 20, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for loratadine syrup (oral suspension), 5 mg / 5
HAWTHORNE, N.Y.--(BUSINESS WIRE)--July 30, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Alclometasone Dipropionate
HAWTHORNE, N.Y., July 29, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for fluconazole tablets in four
HAWTHORNE, N.Y.--(BUSINESS WIRE)--July 29, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for clotrimazole and betamethasone
HAWTHORNE, N.Y.--(BUSINESS WIRE)--July 29, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) today reported results for the Company's second quarter and six months ended June 30, 2004, and provided investors with an update on the progress of the Company's proprietary product pipeline.
HAWTHORNE, N.Y., July 27, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) intends to report financial results for the second quarter of 2004 prior to the Nasdaq market opening on Thursday, July 29, 2004. The Company will conduct a conference call to discuss the results on the
HAWTHORNE, N.Y., June 1, 2004 (PRIMEZONE) -- Taro Pharmaceutical Industries Ltd. (Nasdaq:TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for ammonium lactate lotion, 12%.
HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 29, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO): First Quarter Highlights -- Sales of $84.1 Million Reflect a 22% Increase Over First Quarter of 2003 -- Gross Profit Increases 27% to $56.4 Million, or 67% of Sales -- Increased Marketing Expenses
HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 28, 2004--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) intends to report financial results for the first quarter of 2004 prior to the Nasdaq market opening on Thursday, April 29, 2004. The Company will conduct a conference call to discuss the results on
Alerts are e-mailed to you whenever certain new company information is posted to this site.
